Sunday, November 19, 2017
News
NEWS HOME
»
PRESS RELEASES

Jardiance® reduced risk of cardiovascular death in people with type 2 diabetes and established CV disease* independent of background blood sugar control
  SocialTwist Tell-a-Friend  
   


Date: 13-09-2017 11:17AM
Source: Boehringer Ingelheim
Category: Business/ Finance, Pharmaceutical, General, Science & Research, Healthcare & Biotechnology, Pharmaceutical
Location: Ingelheim, Germany & Indianapolis, United States

Business Wire India

New analyses of the landmark EMPA-REG OUTCOME® trial showed that Jardiance® (empagliflozin) reduced the risk of cardiovascular death in patients with type 2 diabetes and established cardiovascular (CV) disease*, independent of blood sugar control at the start of the study.1 A reduction in cardiovascular death was also seen when Jardiance® was added to common first and second-line diabetes medications, such as metformin or sulphonylurea.2,3 These results from post-hoc analyses were presented by Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Lisbon, Portugal.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170912005928/en/

“Now that we have a new option for reducing the risk of cardiovascular death among people with type 2 diabetes, we are striving to better understand if there are differences in how patients can benefit,” said Prof. Silvio Inzucchi, Section of Endocrinology, Yale School of Medicine, New Haven, USA, who presented the data today. “These new analyses of the EMPA-REG OUTCOME® trial showed empagliflozin was effective in reducing the risk of cardiovascular death in patients with type 2 diabetes and established cardiovascular disease, no matter what the blood sugar levels at the start of the study were or if empagliflozin was added to commonly used oral blood sugar lowering treatments.”

In all four blood sugar level groups at study start (HbA1c levels of <7.0%, 7.0% to <8.0%, 8.0% to <9.0% and ≥9.0%), patients receiving Jardiance® demonstrated a reduction in the risk of cardiovascular death compared with placebo. This was consistent with the risk reduction seen in the overall trial population* and seen irrespective of whether blood sugar control was improved following introduction of the study treatment (as measured by a decrease in HbA1c level of ≥ 0.5% at week 12).1

Additional post-hoc analyses showed that when Jardiance® was added to metformin or sulphonylurea, the reduction of cardiovascular death compared to placebo was consistent with the overall trial population*. These analyses also showed the proportion of patients with hypoglycaemic adverse events were similar between the placebo and Jardiance® groups in the EMPA-REG OUTCOME® trial.2,3

The 7,020-patient EMPA-REG OUTCOME® trial results, first published in the New England Journal of Medicine in 2015, had shown that Jardiance® reduced the relative risk of cardiovascular death by 38 percent compared to placebo in patients with type 2 diabetes and established cardiovascular disease* on top of standard of care (including glucose-lowering agents and cardiovascular drugs). The overall safety profile of Jardiance® was consistent with that of previous clinical trials and current label information.4,5

“Cardiovascular disease is the primary cause of death in people with type 2 diabetes," said David Kendall, M.D., Distinguished Medical Fellow, Lilly Diabetes. “The results presented at EASD provide further evidence of the benefit empagliflozin can provide to patients with different background blood sugar control.”

“The Boehringer Ingelheim and Eli Lilly Diabetes Alliance leads the paradigm shift in the treatment of people with type 2 diabetes”, said Dr Georg van Husen, Corporate Senior Vice President, Head of the Therapeutic Area CardioMetabolism, Boehringer Ingelheim. “The EMPA-REG OUTCOME® trial showed a remarkable reduction in CV death by 38% and the new data indicates that this effect is independent of the blood sugar control."

About Empagliflozin
Empagliflozin (marketed as Jardiance®) is an oral, once daily, highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor approved for use in Europe, the United States and other markets around the world for the treatment of adults with type 2 diabetes.

Inhibition of SGLT2 with empagliflozin in people with type 2 diabetes and high blood sugar levels leads to excretion of excess sugar in the urine. In addition, initiation of empagliflozin increases excretion of salt from the body (i.e. sodium) and reduces the fluid load of the body’s blood vessel system (i.e. intravascular volume). The glucosuria, natriuresis and osmotic diuresis observed with empagliflozin may contribute to the improvement in cardiovascular outcomes.5

Empagliflozin is not for people with type 1 diabetes or for people with diabetic ketoacidosis (increased ketones in the blood or urine).

About EMPA-REG OUTCOME®4
EMPA-REG OUTCOME® was a long-term, multicentre, randomised, double-blind, placebo-controlled trial of more than 7,000 people from 42 countries with type 2 diabetes at high risk for cardiovascular events.

The study assessed the effect of empagliflozin (10 mg or 25 mg once daily) added to standard of care compared with placebo added to standard of care. Standard of care was comprised of glucose-lowering agents and cardiovascular drugs (including for blood pressure and cholesterol). The primary endpoint was defined as time to first occurrence of cardiovascular death, non-fatal heart attack or non-fatal stroke.

Over a median of 3.1 years, Jardiance® significantly reduced the risk of CV death, non-fatal heart attack or non-fatal stroke by 14 percent versus placebo. The risk of CV death was reduced by 38 percent, with no significant difference in the risk of non-fatal heart attack or non-fatal stroke. The overall safety profile of empagliflozin was consistent with that of previous trials.

Intended audiences
This press release is issued from Boehringer Ingelheim Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where Boehringer Ingelheim and Eli Lilly and Company do business.

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Jardiance and its safety profile, and reflects Lilly's current belief.However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there can be no guarantee that future study results will be consistent with the results to date or that Jardiance will receive additional regulatory approvals. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

Please click on the link below for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/EASD-2017

*Adult patients with type 2 diabetes and coronary artery disease, peripheral artery disease, or a history of myocardial infarction or stroke


MULTIMEDIA AVAILABLE :
http://www.businesswire.com/news/home/20170912005928/en/


CONTACTS :

Boehringer Ingelheim
Dr Petra Kienle
Product Communication Manager
Email: press@boehringer-ingelheim.com
Phone: +49 (6132) 77 143877
or
Lilly Diabetes
Molly McCully
Communications
Email: mccully_molly@lilly.com
Phone: +1 (317) 478 5423

More Press Releases

UAE Exchange India Awarded for Business Excellence Award More than Once

Frost & Sullivan and CNI Jointly Host the First Edition of 2017 Nepal Business Excellence Awards in Kathmandu

IH<sup>2*</sup> Technology Licensed to Biozin Holding AS

Madison Realty Capital Provides $64.0 Million Construction Financing for 200 Kent Avenue Development in Williamsburg, Brooklyn

Envion AG: Start-up from the Heart of Berlin Has Pioneered Decentralized Mobile Mining by Combining Blockchain with Regenerative Energy

Double Win for Vocalink at the 2017 Payments Awards

'Housing for All by 2022' gets a Boost with Hike in Unit Size of MIG Houses under Credit Linked Subsidy Scheme: Dr Niranjan Hiranandani

Subcontinent's Photography Icons Gear Up for a UAE Showcase

Smart Contract Security Startup Quantstamp Token Sale Oversubscribed by $9.5M

AstraZeneca to Present Transformative Data at ESMO Asia 2017 Congress from Pivotal Trials Showing Potential New Standards of Care in Non-small Cell Lung Cancer

Kuwait's Jazeera Airways Connects to India with Daily Flights to Hyderabad

Celgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA for Relapsed and Refractory Multiple Myeloma

Mega Business Expo to be Held at Hyderabad on Nov 25-26

Calvin Klein, Inc. Announces Holiday Retail Experience with Amazon Fashion

Rotary World Fest all Set for Another Smashing Festival!

Kellogg India Pvt Ltd amongst Top 100 Best Companies for Women in India

Blenders Pride Fashion Tour 2017 Arrives in Gurugram

CA Technologies Raises the Bar on Digital Trust with A.I. Powered Software and Intelligent Automation

Corporate Social Responsibility Related News Releases and Story Ideas for Reporters, Bloggers and Media Outlets

CA Technologies Delivers Intelligence across its Portfolio to Bring the Modern Software Factory to Life

CA Technologies Introduces Expanded Portfolio to Support DevSecOps with Velocity and Scale

Stage Set for Three Days of Supercross Extravaganza

Time to Market Drastically Reduced for Banks to Deploy MOTION CODE™

2.38 Million Visitors and USD 56 Million Book Sales at Sharjah International Book Fair 2017

Our Telekom to Roll Out First 4G/LTE Network and High-Speed Broadband in Solomon Islands with SES Networks

India-Canada Joint Venture in Medical Electronics to Ensure Affordable Healthcare

Bertin Launches the Sterilwave 100: the Ultra-Compact Solution for the Management of Potentially Infectious Hospital Waste

Bahrain to Host Global Entrepreneurship Congress 2019

Nel ASA: Enters into Exclusive Partnership with Nikola - Awarded Initial Purchase Order for Two Demo Stations

Thousands Convene in Houston to Learn About the Latest In Automation Technology While Helping to Support Area Recovery

Mopria Print Service 2.3 Unleashes New Mobile Printing Capabilities with Share-to-Print from Android Devices

 
TRENDING TOPICS
 
 
 
CITY NEWS
MORE CITIES
INDIA WORLD ASIA
Ravinder Gosain murder: Three suspects s...
Manipur populace resolves to safeguard t...
Sri Lankan Navy apprehends four Indian f...
Telangana CM waives off pending power du...
Children who snore likelier to grow up i...
PM Modi, other national icons congratula...
More...    
 
 Top Stories
'Conspirators' will gain nothing bu... 
'Total' cannot drop major gas deal ... 
A key to stopping cancer in its tra... 
This anti-malaria drug may be new w... 
Assad regime shelling kills 12 civi... 
Situation under control after commu... 
Jaden Smith flaunts gold grills in ... 
Trump's commercial policy could und...